Trinity Biotech Achieves Profitability Milestone After Restructuring

Trinity Biotech announced it has reached a critical profitability inflection point during Q2 2025, marking a significant milestone in its strategic turnaround. The company reported Q1 2025 revenue of $7.6 million and expects substantial revenue growth in Q2 and Q3 2025, driven by ramped-up offshored manufacturing and resumed supply of its flagship rapid HIV test following WHO approval. Operational restructuring, including manufacturing consolidation and offshoring, has significantly reduced costs, positioning Trinity Biotech for sustainable profitability and cash flow positivity from Q3 2025 onward. The company is focusing on expanding its product portfolio, including diabetes care, HIV tests, and pipeline diagnostics like preeclampsia and prostate cancer tests, while advancing a next-generation continuous glucose monitoring solution. Despite the positive outlook, current financial challenges include weak overall performance with negative equity and high debt, impacting stock valuation. Trinity Biotech aims to leverage its leaner structure to drive efficiencies and EBITDA improvements, targeting profitable growth in the near term and beyond.